SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Raewyn M. Poole, Daclatasvir + Asunaprevir: First Global Approval, Drugs, 2014, 74, 13, 1559

    CrossRef

  2. 2
    Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’Boyle, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell, Nicholas A. Meanwell, Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors, Journal of Medicinal Chemistry, 2014, 57, 5, 1643

    CrossRef

  3. 3
    Robert G. Gentles, Min Ding, John A. Bender, Carl P. Bergstrom, Katharine Grant-Young, Piyasena Hewawasam, Thomas Hudyma, Scott Martin, Andrew Nickel, Alicia Regueiro-Ren, Yong Tu, Zhong Yang, Kap-Sun Yeung, Xiaofan Zheng, Sam Chao, Jung-Hui Sun, Brett R. Beno, Daniel M. Camac, Chong-Hwan Chang, Mian Gao, Paul E. Morin, Steven Sheriff, Jeff Tredup, John Wan, Mark R. Witmer, Dianlin Xie, Umesh Hanumegowda, Jay Knipe, Kathy Mosure, Kenneth S. Santone, Dawn D. Parker, Xiaoliang Zhuo, Julie Lemm, Mengping Liu, Lenore Pelosi, Karen Rigat, Stacey Voss, Yi Wang, Ying-Kai Wang, Richard J. Colonno, Min Gao, Susan B. Roberts, Qi Gao, Alicia Ng, Nicholas A Meanwell, John F. Kadow, Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase, Journal of Medicinal Chemistry, 2014, 57, 5, 1855

    CrossRef

  4. 4
    S. BALTER, J. H. STARK, J. KENNEDY, K. BORNSCHLEGEL, K. KONTY, Estimating the prevalence of hepatitis C infection in New York City using surveillance data, Epidemiology and Infection, 2014, 142, 02, 262

    CrossRef

  5. 5
    Sreedhar Chinnaswamy, Genetic Variants at theIFNL3Locus and Their Association with Hepatitis C Virus Infections Reveal Novel Insights into Host-Virus Interactions, Journal of Interferon & Cytokine Research, 2014, 34, 7, 479

    CrossRef

  6. You have free access to this content6
    Mitchell L. Shiffman, Yves Benhamou, HCV F1/F2 patients: treat now or continue to wait, Liver International, 2014, 34,
  7. You have free access to this content7
    Sebastián Marciano, Adrián C. Gadano, How to optimize current treatment of genotype 2 hepatitis C virus infection, Liver International, 2014, 34,
  8. 8
    Philippe Halfon, Denis Ouzan, Tarik Asselah, Christophe Renou, Thierry Allègre, Patrick Delasalle, Alain Lafeuillade, Jean-François Cadranel, Nabil Haddad, Hacène Khiri, Guillaume Pénaranda, Marc Bourlière, Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: A prospective multicenter cohort, Clinics and Research in Hepatology and Gastroenterology, 2014,

    CrossRef

  9. 9
    Mohamad S. Hakim, Michelle Spaan, Harry L. A. Janssen, Andre Boonstra, Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?, Reviews in Medical Virology, 2014, 24, 2
  10. You have free access to this content10
    Lawrence Serfaty, Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?, Liver International, 2014, 34,
  11. 11
    Dietje Elisabeth Fransen van de Putte, Michael Makris, Kathelijn Fischer, Thynn Thynn Yee, Lisa Kirk, Karel Johannes van Erpecum, David Patch, Dirk Posthouwer, Eveline Pauline Mauser-Bunschoten, Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders, Journal of Hepatology, 2014, 60, 1, 39

    CrossRef

  12. You have free access to this content12
    Vincenzo Boccaccio, Savino Bruno, Management of HCV patients with cirrhosis with direct acting antivirals, Liver International, 2014, 34,
  13. You have free access to this content13
    Tarik Asselah, Patrick Marcellin, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir, Liver International, 2014, 34,
  14. 14
    Dennis J. Cada, Jasen Cong, Danial E. Baker, Sofosbuvir, Hospital Pharmacy, 2014, 49, 5, 466

    CrossRef

  15. 15
    Tarik Asselah, Sofosbuvir for the treatment of hepatitis C virus, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 121

    CrossRef

  16. 16
    Hai–Yin Jiang, Min Deng, Yong–Hua Zhang, Hua–Zhong Chen, Qian Chen, Bing Ruan, Specific Serotonin Reuptake Inhibitors Prevent Interferon-α–Induced Depression in Patients With Hepatitis C: A Meta-analysis, Clinical Gastroenterology and Hepatology, 2014, 12, 9, 1452

    CrossRef

  17. 17
    Akira Sato, Masahiro Yamauchi, Takayuki Yamada, Reiko Kumano, Kayo Adachi, Toshiya Ishii, Mikihito Hayashi, Daisuke Kumon, Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia, Clinical Journal of Gastroenterology, 2014, 7, 4, 355

    CrossRef

  18. You have free access to this content18
    Valérie Martel-Laferrière, Douglas T. Dieterich, Treating HCV in HIV 2013: on the cusp of change, Liver International, 2014, 34,
  19. 19
    Eva Poveda, David L. Wyles, Álvaro Mena, José D. Pedreira, Ángeles Castro-Iglesias, Edward Cachay, Update on hepatitis C virus resistance to direct-acting antiviral agents, Antiviral Research, 2014, 108, 181

    CrossRef

  20. You have free access to this content20
    Patrick Marcellin, Tarik Asselah, Viral hepatitis: Impressive advances but still a long way to eradication of the disease, Liver International, 2014, 34,
  21. 21
    Tarik Asselah, ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection, Journal of Hepatology, 2013, 59, 4, 885

    CrossRef

  22. 22
    Sonal Kumar, Ira Jacobson, All Oral HCV Therapies of the Future, Current Hepatitis Reports, 2013, 12, 4, 214

    CrossRef

  23. 23
    Ryan C. Schoenfeld, David L. Bourdet, Ken A. Brameld, Elbert Chin, Javier de Vicente, Amy Fung, Seth F. Harris, Eun K. Lee, Sophie Le Pogam, Vincent Leveque, Jim Li, Alfred S.-T. Lui, Isabel Najera, Sonal Rajyaguru, Michael Sangi, Sandra Steiner, Francisco X. Talamas, Joshua P. Taygerly, Junping Zhao, Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B, Journal of Medicinal Chemistry, 2013, 56, 20, 8163

    CrossRef

  24. 24
    Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Omar D. Lopez, Yuping Qiu, Andrew C. Good, Peter T. Nower, Lourdes Valera, Donald R. O’Boyle, Jin-Hua Sun, Mengping Liu, Robert A. Fridell, Julie A. Lemm, Min Gao, Jay O. Knipe, Nicholas A. Meanwell, Lawrence B. Snyder, HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 15, 4428

    CrossRef

  25. 25
    Geoffrey Dusheiko, Tabinda Burney, Hepatitis C treatment: interferon free or interferon freer?, The Lancet, 2013, 381, 9883, 2063

    CrossRef

  26. 26
    Lisa C. Casey, William M. Lee, Hepatitis C virus therapy update 2013, Current Opinion in Gastroenterology, 2013, 1

    CrossRef

  27. 27
    Dawn M. Torres, Stephen A. Harrison, Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials, Hepatology, 2013, 58, 2
  28. 28
    Tarik Asselah, Sofosbuvir-based interferon-free therapy for patients with HCV infection, Journal of Hepatology, 2013, 59, 6, 1342

    CrossRef

  29. 29
    Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba, Sustained and rapid virological responses in hepatitis C clinical trials, Clinical Investigation, 2013, 3, 11, 1083

    CrossRef

  30. 30
    Alita Mishra, Munkhzul Otgonsuren, Chapy Venkatesan, Mariam Afendy, Madeline Erario, Zobair M. Younossi, The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample, Liver International, 2013, 33, 8
  31. 31
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef